Skip to main content
Erschienen in: hautnah dermatologie 6/2013

18.11.2013 | Zertifizierte Fortbildung

Hoffnung bei Haarverlust

Diagnostik und Therapie von Effluvium und Alopezie

verfasst von: Prof. Dr. med. Hans Wolff

Erschienen in: hautnah dermatologie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Verlust von Haaren ist emotional sehr belastend, da bewusst oder unbewusst für viele Menschen gilt: Kräftige Haare = Gesundheit und Jugend, Haarlosigkeit = Krankheit und Alter. Die Nachfrage nach Beratung bei Haarwuchsproblemen ist sehr groß, und letztlich ist der Hautarzt gefordert, kompetent Auskunft zu geben.
Literatur
1.
Zurück zum Zitat Paus, R. and G. Cotsarelis, The biology of hair follicles. N Engl J Med, 1999. 341(7): p. 491–7.PubMedCrossRef Paus, R. and G. Cotsarelis, The biology of hair follicles. N Engl J Med, 1999. 341(7): p. 491–7.PubMedCrossRef
2.
Zurück zum Zitat Courtois, M., et al., Periodicity in the growth and shedding of hair. Br J Dermatol, 1996. 134: p. 47–54.PubMedCrossRef Courtois, M., et al., Periodicity in the growth and shedding of hair. Br J Dermatol, 1996. 134: p. 47–54.PubMedCrossRef
3.
Zurück zum Zitat Hamilton, J.B., Male hormone stimulation is a prerequisite and an incitant in common baldness. Am J Anat, 1942. 71: p. 451–480.CrossRef Hamilton, J.B., Male hormone stimulation is a prerequisite and an incitant in common baldness. Am J Anat, 1942. 71: p. 451–480.CrossRef
4.
Zurück zum Zitat Hillmer, A.M., et al., Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet, 2005. 77(1): p. 140–8.PubMedCrossRef Hillmer, A.M., et al., Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet, 2005. 77(1): p. 140–8.PubMedCrossRef
5.
Zurück zum Zitat Yip, L., N. Rufaut, and R. Sinclair, Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol, 2011. 52(2): p. 81–8.PubMedCrossRef Yip, L., N. Rufaut, and R. Sinclair, Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol, 2011. 52(2): p. 81–8.PubMedCrossRef
6.
Zurück zum Zitat Wolff, H. and C. Kunte, Die androgenetische Alopezie des Mannes - Pathogenese und Therapie. Z Hautkr, 1999. 74: p. 201–208. Wolff, H. and C. Kunte, Die androgenetische Alopezie des Mannes - Pathogenese und Therapie. Z Hautkr, 1999. 74: p. 201–208.
7.
Zurück zum Zitat Hamilton, J.B., Patterned loss of hair in man: types and incidence. Ann NY Acad Sci, 1951. 53: p. 708–728.PubMedCrossRef Hamilton, J.B., Patterned loss of hair in man: types and incidence. Ann NY Acad Sci, 1951. 53: p. 708–728.PubMedCrossRef
8.
Zurück zum Zitat Norwood, O.T., Male pattern baldness: classification and incidence. South Med J, 1975. 68: p. 1359–1365.PubMedCrossRef Norwood, O.T., Male pattern baldness: classification and incidence. South Med J, 1975. 68: p. 1359–1365.PubMedCrossRef
9.
Zurück zum Zitat Kaufman, K.D., et al., Finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Am Acad Dermatol, 1998. 36: p. 578–589.CrossRef Kaufman, K.D., et al., Finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Am Acad Dermatol, 1998. 36: p. 578–589.CrossRef
10.
Zurück zum Zitat Group, T.F.M.P.H.L.S., Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol, 2002. 12: p. 38–49. Group, T.F.M.P.H.L.S., Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol, 2002. 12: p. 38–49.
11.
Zurück zum Zitat Whiting, D.A., et al., Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol, 2003. 13(2): p. 150–60.PubMed Whiting, D.A., et al., Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol, 2003. 13(2): p. 150–60.PubMed
12.
Zurück zum Zitat Olsen, E.A., et al., A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol, 2002. 47(3): p. 377–85.PubMedCrossRef Olsen, E.A., et al., A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol, 2002. 47(3): p. 377–85.PubMedCrossRef
13.
Zurück zum Zitat Yano, K., L.F. Brown, and M. Detmar, Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest, 2001. 107: p. 409–417.PubMedCrossRef Yano, K., L.F. Brown, and M. Detmar, Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest, 2001. 107: p. 409–417.PubMedCrossRef
14.
Zurück zum Zitat Arca, E., et al., An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology, 2004. 209(2): p. 117–25.PubMedCrossRef Arca, E., et al., An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology, 2004. 209(2): p. 117–25.PubMedCrossRef
15.
Zurück zum Zitat Saraswat, A. and B. Kumar, Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol, 2003. 139(9): p. 1219–21.PubMedCrossRef Saraswat, A. and B. Kumar, Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol, 2003. 139(9): p. 1219–21.PubMedCrossRef
16.
Zurück zum Zitat Halsner, U.E. and M.W. Lucas, New aspects in hair transplantation for females. Dermatol Surg, 1995. 21(7): p. 605–10.PubMedCrossRef Halsner, U.E. and M.W. Lucas, New aspects in hair transplantation for females. Dermatol Surg, 1995. 21(7): p. 605–10.PubMedCrossRef
17.
Zurück zum Zitat Yip, L., et al., Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol, 2009. 161(2): p. 289–94.PubMedCrossRef Yip, L., et al., Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol, 2009. 161(2): p. 289–94.PubMedCrossRef
18.
Zurück zum Zitat Birch, M.P., J.F. Messenger, and A.G. Messenger, Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol, 2001. 144: p. 297–304.PubMedCrossRef Birch, M.P., J.F. Messenger, and A.G. Messenger, Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol, 2001. 144: p. 297–304.PubMedCrossRef
19.
Zurück zum Zitat Sinclair, R., et al., Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol, 2011. 165 Suppl 3: p. 12–8.PubMedCrossRef Sinclair, R., et al., Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Br J Dermatol, 2011. 165 Suppl 3: p. 12–8.PubMedCrossRef
20.
Zurück zum Zitat Ludwig, E., Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol, 1977. 97: p. 247–254.PubMedCrossRef Ludwig, E., Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol, 1977. 97: p. 247–254.PubMedCrossRef
21.
22.
Zurück zum Zitat Blume-Peytavi, U., et al., Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau. J Dtsch Dermatol Ges, 2007. 5(5): p. 391–5.PubMedCrossRef Blume-Peytavi, U., et al., Vergleich der Wirksamkeit und Sicherheit von Minoxidil und Alfatradiol bei der topischen Behandlung der androgenetischen Alopezie der Frau. J Dtsch Dermatol Ges, 2007. 5(5): p. 391–5.PubMedCrossRef
23.
Zurück zum Zitat Sinclair, R., M. Wewerinke, and D. Jolley, Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005. 152: p. 466–73.PubMedCrossRef Sinclair, R., M. Wewerinke, and D. Jolley, Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005. 152: p. 466–73.PubMedCrossRef
25.
Zurück zum Zitat Vexiau, P., et al., Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol, 2002. 146: p. 992–999.PubMedCrossRef Vexiau, P., et al., Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol, 2002. 146: p. 992–999.PubMedCrossRef
26.
Zurück zum Zitat Lucky, A.W., et al., A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol, 2004. 50(4): p. 541–53.PubMedCrossRef Lucky, A.W., et al., A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol, 2004. 50(4): p. 541–53.PubMedCrossRef
27.
Zurück zum Zitat van Zuuren, E.J., Z. Fedorowicz, and B. Carter, Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol, 2012. 167(5): p. 995–1010.PubMedCrossRef van Zuuren, E.J., Z. Fedorowicz, and B. Carter, Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol, 2012. 167(5): p. 995–1010.PubMedCrossRef
28.
Zurück zum Zitat Yano, K.,..., and M. Detmar, Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J Invest Dermatol, 2003. 120: p. 14–19.PubMedCrossRef Yano, K.,..., and M. Detmar, Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. J Invest Dermatol, 2003. 120: p. 14–19.PubMedCrossRef
29.
Zurück zum Zitat Messenger, A.G. and J. Rundegren, Minoxidil: mechanisms of action on hair growth. Br J Dermatol, 2004. 150(2): p. 186–94.PubMedCrossRef Messenger, A.G. and J. Rundegren, Minoxidil: mechanisms of action on hair growth. Br J Dermatol, 2004. 150(2): p. 186–94.PubMedCrossRef
30.
Zurück zum Zitat Dawber, R.P. and J. Rundegren, Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol, 2003. 17(3): p. 271–5.PubMedCrossRef Dawber, R.P. and J. Rundegren, Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol, 2003. 17(3): p. 271–5.PubMedCrossRef
31.
Zurück zum Zitat Hoffmann, R. and R. Happle, Alopecia areata - Klinik, Atiologie, Pathogenese. Hautarzt, 1999. 50: p. 222–231.CrossRef Hoffmann, R. and R. Happle, Alopecia areata - Klinik, Atiologie, Pathogenese. Hautarzt, 1999. 50: p. 222–231.CrossRef
32.
Zurück zum Zitat Tosti, A., S. Bellavista, and M. Iorizzo, Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol, 2006. 55(3): p. 438–41.PubMedCrossRef Tosti, A., S. Bellavista, and M. Iorizzo, Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol, 2006. 55(3): p. 438–41.PubMedCrossRef
33.
Zurück zum Zitat Redler, S., et al., Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br J Dermatol, 2012. 167(6): p. 1360–1365.PubMedCrossRef Redler, S., et al., Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br J Dermatol, 2012. 167(6): p. 1360–1365.PubMedCrossRef
34.
Zurück zum Zitat Wolff, H., Haarwachstumsstörungen. Kinder und Jugendmedizin, 2011. 11: p. 343–348. Wolff, H., Haarwachstumsstörungen. Kinder und Jugendmedizin, 2011. 11: p. 343–348.
35.
Zurück zum Zitat Hautmann, G., J. Hercegova, and T. Lotti, Trichotillomania. J Am Acad Dermatol, 2002. 46: p. 807–821.PubMedCrossRef Hautmann, G., J. Hercegova, and T. Lotti, Trichotillomania. J Am Acad Dermatol, 2002. 46: p. 807–821.PubMedCrossRef
36.
Zurück zum Zitat Hoffmann, R. and R. Happle, Alopecia areata - Therapie. Hautarzt, 1999. 50: p. 310–315.CrossRef Hoffmann, R. and R. Happle, Alopecia areata - Therapie. Hautarzt, 1999. 50: p. 310–315.CrossRef
37.
Zurück zum Zitat Gilhar, A., A. Etzioni, and R. Paus, Alopecia areata. N Engl J Med, 2012. 366(16): p. 1515–25.PubMedCrossRef Gilhar, A., A. Etzioni, and R. Paus, Alopecia areata. N Engl J Med, 2012. 366(16): p. 1515–25.PubMedCrossRef
38.
Zurück zum Zitat van der Steen, P., et al., Alopecia areata. Klinik, Pathogenese und topische Immuntherapie. Dt Ärztebl, 1995. 92(12 (A)): p. 831–836. van der Steen, P., et al., Alopecia areata. Klinik, Pathogenese und topische Immuntherapie. Dt Ärztebl, 1995. 92(12 (A)): p. 831–836.
39.
40.
41.
Zurück zum Zitat Powell, J.J., R.P.R. Dawber, and K. Gatter, Folliculitis decalvans including tufted folliculitis: clinical, histological and therapeutic findings. Br J Dermatol, 1999. 140: p. 328–333.PubMedCrossRef Powell, J.J., R.P.R. Dawber, and K. Gatter, Folliculitis decalvans including tufted folliculitis: clinical, histological and therapeutic findings. Br J Dermatol, 1999. 140: p. 328–333.PubMedCrossRef
42.
Zurück zum Zitat Stockmeier, M., et al., Folliculitis decalvans - Behandlung mit einer systemischen Rifampicin-Clindamycin-Kombinationstherapie bei 17 Patienten. Akt Dermatol, 2001. 27: p. 361–363.CrossRef Stockmeier, M., et al., Folliculitis decalvans - Behandlung mit einer systemischen Rifampicin-Clindamycin-Kombinationstherapie bei 17 Patienten. Akt Dermatol, 2001. 27: p. 361–363.CrossRef
43.
Zurück zum Zitat Mehregan, D.A., H.M. van Hale, and S.A. Muller, Lichen planopilaris: clinical and pathologic study of forty-five patients. J Am Acad Dermatol, 1992. 27: p. 935–942.PubMedCrossRef Mehregan, D.A., H.M. van Hale, and S.A. Muller, Lichen planopilaris: clinical and pathologic study of forty-five patients. J Am Acad Dermatol, 1992. 27: p. 935–942.PubMedCrossRef
44.
Zurück zum Zitat Tan, E., et al., Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol, 2004. 50(1): p. 25–32.PubMedCrossRef Tan, E., et al., Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol, 2004. 50(1): p. 25–32.PubMedCrossRef
45.
Zurück zum Zitat Mirmirani, P. and P. Karnik, Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol, 2009. 145(12): p. 1363–6.PubMedCrossRef Mirmirani, P. and P. Karnik, Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol, 2009. 145(12): p. 1363–6.PubMedCrossRef
46.
Zurück zum Zitat Kossard, S., Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol, 1994. 130: p. 770–774.PubMedCrossRef Kossard, S., Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol, 1994. 130: p. 770–774.PubMedCrossRef
47.
Zurück zum Zitat Kossard, S., M.S. Lee, and B. Wilkinson, Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol, 1997. 36: p. 59–66.PubMedCrossRef Kossard, S., M.S. Lee, and B. Wilkinson, Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol, 1997. 36: p. 59–66.PubMedCrossRef
48.
Zurück zum Zitat MacDonald, A., C. Clark, and S. Holmes, Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol, 2012. 67(5): p. 955–61.PubMedCrossRef MacDonald, A., C. Clark, and S. Holmes, Frontal fibrosing alopecia: a review of 60 cases. J Am Acad Dermatol, 2012. 67(5): p. 955–61.PubMedCrossRef
Metadaten
Titel
Hoffnung bei Haarverlust
Diagnostik und Therapie von Effluvium und Alopezie
verfasst von
Prof. Dr. med. Hans Wolff
Publikationsdatum
18.11.2013
Verlag
Urban & Vogel
Erschienen in
hautnah dermatologie / Ausgabe 6/2013
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-013-1653-8

Weitere Artikel der Ausgabe 6/2013

hautnah dermatologie 6/2013 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.